HER2 is a transmembrane tyrosine kinase (TK) receptor, whose overexpression often leads to adverse clinical outcomes in breast cancer and reduces sensitivity to various chemotherapy drugs and hormones. This evidence concerns the gene ERBB2 and breast cancer.